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Background: Graphene and graphene derivative nanoplatelets represent a new generation of nanomaterials with
unique physico-chemical properties and high potential for use in composite materials and biomedical devices. To date
little is known about the impact graphene nanomaterials may have on human health in the case of accidental or
intentional exposure. The objective of this study was to assess the cytotoxic potential of graphene nanoplatelets with
different surface chemistry towards a human hepatoma cell line, Hep G2, and identify the underlying toxicity targets.
Methods: Graphene oxide (GO) and carboxyl graphene (CXYG) nanoplatelet suspensions were obtained in water and
culture medium. Size frequency distribution of the suspensions was determined by means of dynamic light scattering.
Height, lateral dimension and shape of the nanoplatelets were determined using atomic force and electron
microscopy. Cytotoxicity of GO and CXYG nanoplatelets was assessed in Hep G2 cells using a battery of assays covering
different modes of action including alterations of metabolic activity, plasma membrane integrity and lysosomal
function. Induction of oxidative stress was assessed by measuring intracellular reactive oxygen species levels. Interaction
with the plasma membrane, internalization and intracellular fate of GO and CXYG nanoplatelets was studied by
scanning and transmission electron microscopy.
Results: Supplementing culture medium with serum was essential to obtain stable GO and CXYG suspensions. Both
graphene derivatives had high affinity for the plasma membrane and caused structural damage of the latter at
concentrations as low as 4 μg/ml. The nanoplatelets penetrated through the membrane into the cytosol, where they
were concentrated and enclosed in vesicles. GO and CXYG accumulation in the cytosol was accompanied by an
increase in intracellular reactive oxygen species (ROS) levels, alterations in cellular ultrastructure and changes in
metabolic activity.
Conclusions: GO and CXYG nanoplatelets caused dose- and time-dependent cytotoxicity in Hep G2 cells with
plasma membrane damage and induction of oxidative stress being important modes of toxicity. Both graphene
derivatives were internalized by Hep G2, a non-phagocytotic cell line. Moreover, they exerted no toxicity when
applied at very low concentrations (< 4 μg/ml). GO and CXYG nanoplatelets may therefore represent an attractive
material for biomedical applications.
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Graphene is an allotrop of carbon, which consists of a
two-dimensional (2D) crystalline lattice of hexagonally
arranged, sp2-hybridized carbon atoms [1]. Although
graphene-like structures have been studied since the
middle of the 20th-century [2-4] and free-standing
ultrathin graphene sheets have been already imaged in
1962 by Boehm et al. [1], it was not until 2004 that large,
single-layered graphene sheets were successfully isolated
[5,6]. The ground-breaking experiments by Konstantin
Novoselov and Andre Geim, for which they received the
2010 Novel Prize in Physics [7] have paved the way for
further fundamental and application-orientated research
on this unique material (a “title search” on “graphene” in
the ISI Web of Knowledge data base in October 2012
yielded over 19,000 scientific publications since 2005. In
comparison, only 84 publications were found for the
time before 2005). Multitudinous studies carried out
since then revealed that graphene possesses a variety of
exceptional physico-chemical properties [8]. Owing to
these properties graphene represents an attractive mater-
ial for a wide range of technical applications. Indeed, the
number of filed patents related to graphene has been ex-
ponentially increasing over the last years, reaching al-
most 1000 filed patents by October 2012 [9]. While the
research and development of graphene-based electronics
is still in its very initial state and the appearance of such
electronic devices on the market within the next two de-
cades is rather unlikely [10], the use of graphene in com-
posite materials (similar to those developed using
carbon nanotubes) to enhance the latter’s thermal, elec-
tric or mechanical properties may not be that far ahead
(especially when considering the feasibility of graphene
for mass production at low cost) [11]. Many of the com-
posite materials described in patent applications contain
platelets of graphene (or oxidized graphene) with lateral
dimensions in the nanoscale [12]. Obviously, graphene
(or graphene derivative) nanoplatelets permanently em-
bedded in a material matrix pose a low risk to human
and environmental health due to low exposure. How-
ever, a realistic risk may exist for people working in
manufacturing of graphene nano-powder as well as for
downstream-users (processing, research and develop-
ment). Therefore, it is necessary to assess the toxic ef-
fects graphene nanoplatelets may exhibit in case of
accidental exposure (e.g. through inhalation) [13]. In
addition to the broad range of technical applications,
nano-sized graphene sheets also attract increasing atten-
tion from the biomedical research community [14]. As for
other carbon-based nanomaterials such as carbon na-
notubes or fullerenes, surface functionalization of the
graphene nanoplatelets is a prerequisite for their use in bio-
medical applications. Two surface-functionalized graphene
derivatives, which are used as platform for biomedicalapplications are graphene oxide (GO) and carboxyl
graphene (CXYG) [15]. GO is characterized through the
presence of epoxy groups (1–2 ethers) and tertiary hydroxy
groups on the basal plane, and lactols, keton, carboxylic
acid and ester groups at the edges of the sheet [16-18].
CXYG has a similar chemical structure, but has a higher
carboxyl ratio and additionally features ethanoic acid
groups (−O-CH2-COOH) on sp
3-hybridized carbon on
the basal plane (derived from -OH or -C-OH). Oxidized
graphene nanomaterials were demonstrated to be able to
serve as efficient carrier systems for the targeted delivery
of chemical drugs [19-22] and biomolecules including pro-
teins, DNA and siRNA [23-26] Furthermore, the potential
of GO for biosensing [27,28] and bioimaging applications
is being explored [29-32]. The feasibility of graphene- and
GO-composite materials to enhance the performance of
implants and tissue engineering scaffolds is also being in-
vestigated [33-36].
Even though the research on technical and biomedical
applications of graphene and graphene derivative nano-
materials is expanding rapidly, relatively little is known
about their interaction with biological systems or intrinsic
toxicity [37]. The sparse literature published on in vitro
toxicity of graphene nanomaterials suggest that, analogous
to other carbon nanomaterials, physico-chemical charac-
teristics may play a critical role in the biological activity of
this novel class of nanomaterials [38-40]. Mechanisms that
were suggested to underlie the cytotoxic effect include
plasma membrane damage [38,41-43], impairment of
mitochondrial activity [42,44], induction of oxidative
stress [40,42,44,45] and DNA damage [46] eventually lead-
ing to apoptotic and/or necrotic cell death [38,42,44,47].
Yet, in some cases, results regarding the cytotoxicity of
graphene-based nanomaterials obtained by different au-
thors are conflicting (in particular that for GO). These dis-
crepancies may be due to differences in the intrinsic
properties of the nanomaterials tested, the availability of
the nanomaterial during the assay or the sensitivity of the
cell lines used (among other factors). Furthermore, con-
sidering the extremely high specific surface area of
graphene nanomaterials and their chemical nature (conju-
gated π-electron system, presence of reactive functional
surface groups), they can be expected to interfere with
most of the commonly used bioassay(s) (e.g. physical sorp-
tion of assay reagents to the nanomaterial surface,
quenching of fluorescent probes, autofluorescence of the
nanomaterial). Difficulties in assessing the degree of inter-
ference of the tested nanomaterials with the assays
employed may have lead to false positive or negative re-
sults, and thus could explain some of the inter-study dif-
ferences detected.
The objective of this study was to evaluate the cyto-
toxicity and identify the underlying mechanisms of tox-
icity of two different oxygen-functionalized graphene
Figure 1 Size distribution of GO and CXYG in stock suspensions
determined by means of DLS. GO (A) and CXYG (B) stock
suspensions diluted to concentrations of 16 and 32 μg/ml,
respectively, were analyzed by means of DLS. The graphs show the
average hydrodynamic size distribution by intensity of at least four
measurements consecutively conducted on each sample.
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cell line. As stated above, both graphene derivatives are
explored for their use in technical and biomedical appli-
cations, so that both accidental and intentional exposure
may occur. Moreover, they represent the basic building
block of other carbon nanomaterials, such as (hydroxyl-
ated and/or carboxylated) fullerenes or carbon nano-
tubes [10]. The latter have been demonstrated to be
subject to chemical and biological degradation yielding
breakdown products with hydrodynamic diameters in
the submicron range [48-51]. The evaluation of the toxic
potential of nano-sized graphene platelets may thus not
only contribute to a better understanding of the intrinsic
toxicity of engineered graphene nanomaterials, but also
of graphene nanoplatelets that could potentially origin-
ate from degradation of other graphene-based nano-
materials. A human hepatocellular carcinoma cell line
was chosen for performing the experiments, because in
the case of exposure (for instance due to accidental in-
halation or due to intentional introduction of graphene-
based biomedical applications) graphene nanoplatelets
may enter the circulatory system and accumulate in the
liver [13,52-54]. The Hep G2 cell line was selected in
particular because according to a preliminary screening
of four hepatoma cell lines (Hep G2, H4IIE, RTH149
and PLHC-1) it was one of the most sensitive for GO
and CXYG.
Here we report that GO and CXYG nanoplatelets
physically interact with Hep G2 cells and cause plasma
membrane damage. Exposure to GO and CXYG was fur-
thermore found to induce oxidative stress and alter
metabolic activity and cell ultrastructure. Moreover, we
provide new insights into the interaction of graphene
nanoplatelets with the plasma membrane, their internal-
ization and intracellular fate.
Results
Characterization of GO and CXYG stock suspensions
Dynamic light scattering
GO and CXYG could be readily dispersed in Milli-Q
water (at 1 mg/ml) by means of ultrasonication. Yet,
DLS and light microscopy analysis indicated that the
suspensions contained large aggregates/agglomerates
(Additional file 1: Figures S1 and S2, respectively).
The aggregates/agglomerates were eliminated by means of
centrifugation (Additional file 1: Figures S1 and S2, re-
spectively). The concentration of the supernatants could
be successfully estimated using concentration-absorbance
standard curves generated from aliquots of the non-
centrifuged GO and CXYG suspensions (Curves generated
from the non-centrifuged suspensions and curves gener-
ated from the supernatant had the same slope) (Additional
file 1: Figure S3). Results of DLS measurements performed
on these suspensions (in the following text referred to asstock suspensions) met the quality criteria set by the
Zetasizer Software. In the GO stock suspension three size
populations with average hydrodynamic diameters of
71.4 ± 20, 385.9 ± 18.6 and 4775 nm were identified, with
the 385 nm population predominating in terms of inten-
sity (relative intensity: 99.5%) (Figure 1A). In the CXYG
stock suspension three size populations with average
hydrodynamic diameters of 260.8 ± 24.5, 1110.4 ± 175.3
and 5290.5 ± 107.2 nm could be detected. The relative
intensities of the corresponding peaks were 12.6, 85.4
and 2.0%, respectively (Figure 1B).
The ζ-potential of the GO and CXYG stock suspen-
sions was −8.3 mV and −55.1 mV, respectively. Both
stock suspensions demonstrated high colloidal stability
and could be stored at 4°C for several months without
any visible sedimentation or changes in size distribution
(Additional file 1: Figure S4).
Atomic force microscopy
AFM analysis of aliquots of the GO stock suspension re-
vealed that the majority of the imaged GO platelets had
a uniform height of 0.8 - 0.9 nm (Figure 2A), i.e. were
single-layered [11]. The platelets had rather smooth con-
tours and were of heterogeneous shape. The lateral
dimension of the imaged platelets (or aggregates/ag-
glomerates) was of several tens to hundreds of nano-
meters. A frequency distribution established from size
measurements performed on the AFM images (surface
area of the individual platelets, three different images,
900 counts) demonstrated that about 95% of the GO
platelets had dimensions smaller than 5000 nm2, and
Figure 2 AFM topographic images of GO and CXYG stock suspensions. Both stock suspensions comprised nanoplatelets of heterogeneous
size and shape. For illustration purposes, the lateral dimension of some GO and CXYG nanoplatelets is displayed in the images (white arrows).
Red arrows exemplarily indicate small nanoplatelets whose lateral dimension could not be measured. Height measurements performed on GO
stock suspensions (A) indicated that GO nanoplatelets were single-layered (~0.8 nm). Height measurements performed on CXYG stock
suspensions (B) indicated that CXYG nanoplatelets were both single- and few-layered (0.8 - 2.4 nm). Examples of height profiles are presented
below the corresponding topographic images (section along the white line visible in the AFM image).
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(Additional file 1: Figure S5) (For illustrative purposes: If
the platelets had a disc-like shape, the above stated areas
would correspond to platelets with diameters of about
80 and 35 nm, respectively). GO platelets with lateral
dimensions of > 1 μm were also observed but sparse
(Additional file 1: Figure S6).
In the CXYG stock suspensions, both single-layered
and multi-layered platelets were identified. The height
of as single-layered interpreted CXYG was ~ 0.8 nm.
Most of the multi-layered CXYG had a thickness
of ~1.6 or ~2.4 nm, i.e. consisted of two or three car-
bon layers (Figure 2B). CXYG platelets had sharp-
edged contours and were heterogeneous in shape. For
CXYG no size distribution could be generated, because
CXYG platelets in AFM images were superimposed suchthat measurements of the area of the individual platelets
were not possible. The approximate lateral dimension
of the imaged platelets ranged from 100 nm to 1 μm
(length) (Figure 2B).
Transmission electron microscopy
TEM micrographs of the GO stock suspension dem-
onstrated GO nanoplatelets of homogenous, round
shape with lateral dimensions in the lower nanometer
range (<50 nm). GO nanoplatelets were either present
as individual particles or in the form of larger ag-
gregates/agglomerates with lateral dimension ranging
from several tens to several hundreds of nanometers
of nanometers (Figure 3A). TEM micrographs of
CXYG stock suspensions demonstrated CXYG nano-
platelets with lateral dimensions of a few to several
Figure 3 TEM micrographs of GO and CXYG stock suspensions.
TEM images of GO stock suspensions (A) demonstrated aggregates/
agglomerates of GO nanoplatelets with lateral dimensions in the
lower nanometer range. TEM images of CXYG stock suspensions
(B) demonstrated comparatively larger, thin sheets. The inserts in the
upper right corner of the images show the boxed-in areas at higher
magnification. The large round holes visible in both micrographs
represent defects in the carbon coating of the copper grid. The
scale bar represented in the lower left corner of the images
corresponds to 200 nm.
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wrinkles (Figure 3B).Characterization of GO and CXYG suspensions in cell
culture medium
Influence of culture medium composition on colloidal
stability of GO and CXYG nanoplatelets
GO and CXYG demonstrated different stability depend-
ing on the composition of the cell culture medium
(Additional file 2: Figure S1). In the least complex
medium (MEM) flocculation of GO and CXYG oc-
curred within the first 5 min. In MEM supplemented
with L-Gln and P/S flocculation occurred even almost
instantly and was followed by rapid sedimentation of
GO and CXYG aggregates/agglomerates. In contrast no
flocculation and/or sedimentation were observed in the
cell culture medium supplemented with 10% FBS. Nomajor differences were observed regarding the suspension
properties of the two graphene derivatives (Additional file
2: Figure S1).
Hydrodynamic size distribution and colloidal stability of GO
and CXYG suspensions used for cell treatment
DLS analysis of GO and CXYG suspensions in serum-
supplemented medium resulted in five intensity peaks,
three of which represented nanomaterial populations. The
other peaks corresponded to culture medium components.
The mean hydrodynamic diameters, the corresponding
standard deviations and the relative intensity of all peaks
are shown in Tables 1 and 2. The size distribution profiles
in form of histograms are represented in Additional file 2:
Figures S2 and S3. Note that DLS does not give accurate
results for non-spherical particles such as those tested in
this study. Yet, it can provide valuable information about
changes in the aggregation/agglomeration state of the par-
ticles in course of the experiment or dependent on the di-
lution stage of the suspension. The GO populations
detected in the highest concentrated GO sample (16 μg/ml)
had an average hydrodynamic diameter of 42.0 ± 11.3,
382.9 ± 22.0 and 4672.5 ± 414.9 nm (Table 1, peak 3, 4
and 5, respectively), i.e. resembled those detected in the
GO stock suspension. The hydrodynamic diameter of the
identified GO size populations did not change with in-
creasing sample dilution or incubation time (see Table 1
and Additional file 2: Figure S2). The CXYG suspension
contained larger platelets (or aggregates/agglomerates)
than the GO suspension. The three size populations that
were identified in the highest concentrated CXYG sample
had an average hydrodynamic diameter of 349.5 ± 42.6,
1805.6 ± 616.8 and 4827.3 ± 497.5 nm (Table 2, peak 3,
4 and 5, respectively). In comparison to the GO suspension,
the size distribution profile of the CXYG suspension
changed as it was further diluted. Yet, no major changes
were observed with increasing incubation time (see Table 2
and Additional file 2: Figure S3). The ζ-potential of the
GO and GXYG in serum-supplemented medium was
−9.1 mV and −10.2 mV, respectively (the ζ--potential
of the medium alone was −0.02 mV).
Autofluorescence of GO and CXYG
Fluorescence spectra of GO and CXYG stock sus-
pensions (diluted to 10 μg/ml) did not show any signi-
ficant fluorescence at the excitation/emission wave
lengths that were used in the CFDA-AM, ROS (in both
assays 485/535 nm), alamarBlue, MMP (in both assays
532/590 nm) and fluorescamine assay (360/450 nm)
(Additional file 3: Figure S1). Since emission was only
recorded at wavelengths between 250 and 600 nm, no infor-
mation was obtained if GO or CXYG may fluoresce at the
excitation and emission wavelengths used in the NRU assay
(532 and 680 nm, respectively). Yet, no autofluorescence
Table 1 Hydrodynamic size distribution in GO suspensions as function of concentration and incubation time
GO in MEM+ Average hydrodynamic diameter Relative intensity
Time Conc. Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 PdI
[hrs] [μg/ml] d. ± SD [nm] d. ± SD [nm] d. ± SD [nm] d. ± SD [nm] d. ± SD [nm] [%] [%] [%] [%] [%]
0 16 4.39 n =1 9.8 ± 2.0 42.0 ± 11.3 382.9 ± 22.0 4672.5 ± 414.9 0.3 9.6 7.4 81.7 1.0 0.7
0 8 1.25 n =1 9.2 ± 2.5 34.4 ± 12.7 314.4 ± 44.0 5140.8 ± 47.3 0.6 13.7 12.2 72.5 1.1 0.9
0 4 - - 10.0 ± 1.4 35.9 ± 10.3 336.0 ± 38.3 5069.5 ± 163.7 0.0 19.1 17.2 62.7 1.0 1.0
0 2 - - 9.9 ± 1.2 41.9 ± 7.8 333.8 ± 34.3 4899.4 ± 189.3 0.0 29.6 24.8 44.2 1.7 0.8
48 16 - - 8.1 ± 1.0 32.5 ± 11.7 367.9 ± 18.6 5081.3 ± 201.5 0.0 7.17 8.1 84.0 0.7 0.7
48 8 - - 9.5 ± 1.0 36.2 ± 7.1 682.4 ± 96.6 4182.0 ± 514.9 0.0 10.1 7.5 78.8 2.8 1.0
48 4 - - 9.0 ± 0.4 38.6 ± 5.0 389.0 ± 16.1 - 0.0 19.1 17.1 63.9 0.0 1.0
48 2 - - 9.6 ± 0.9 37.1 ± 7.6 363.5 ± 50.8 5043.0 n =1 0.0 27.3 21.8 50.6 0.3 0.9
120 16 - - 9.8 ± 0.6 56.4 ± 19.2 683.7 ± 99.7 4596.3 ± 381.1 0.0 6.2 6.2 85.0 2.7 0.7
120 8 - - 9.0 ± 1.1 39.1 ± 14.4 346.9 ± 21.2 4796.5 ± 95.5 0.0 8.8 9.1 81.4 0.7 0.7
120 4 - - 9.8 ± 1.0 33.5 ± 5.5 357.7 ± 33.1 5103.3 ± 145.7 0.0 19.2 14.1 66.2 0.7 1.0
120 2 - - 10.7 ± 1.2 42.4 ± 9.0 334.2 ± 46.0 4914.7 ± 109.4 0.0 31.3 16.1 51.5 1.2 0.9
blank - - 9.6 ± 0.4 62.4 ± 2.5 - 4268.5 ± 129.9 0.0 49.6 46.9 0.0 3.5 0.5
DLS analysis was performed on serial dilutions of a GO suspension (16 μg/ml) prepared in culture medium supplemented with 10% FBS (MEM+). The samples
were analyzed directly after preparation as well as after incubation at 37°C for 48 and 120 h, respectively. The average hydrodynamic size is represented as mean
diameter (d.) ± standard deviation (SD) in nm. Data are from six consecutively performed measurements. The relative intensities of the size peaks are indicated in
[%], respectively. The polydispersity index (PdI) of the analyzed samples is shown in the last column. “n = 1” indicates that no SD could be calculated since the
peak was detected in only one of the six performed measurements. The minus (“-“) indicates that no peak could be identified at the respective dilution stage.
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cluded in the assay plate (data not shown).
Redox-interaction of GO and CXYG with alamarBlue
No acellular reduction of resazurine was observed upon incu-
bation of the dye (1.25% v/v) with increasing concentrations ofTable 2 Hydrodynamic size distribution in CXYG suspensions
CYXG in MEM+ Average hydrodynamic diameter
Time Conc. Peak 1 Peak 2 Peak 3 Peak 4
[hrs] [μg/ml] d. ± SD [nm] d. ± SD [nm] d. ± SD [nm] d. ± SD [n
0 32 - - - 349.5 ± 42.6 1805.6 ± 6
0 16 5.4 n = 1 52.5 ± 9.8 342.5 ± 74.5 2333.8 ± 3
0 8 10.2 ± 1.9 35.1 ± 9.2 116.2 ± 33.3 796.8 ± 6
0 4 9.7 ± 1.4 41.2 ± 9.3 153.1 ± 8.2 821.7 ± 17
48 32 - - - 259.3 ± 33.1 1451.3 ± 3
48 16 9.7 ± 2.1 20.4 ± 1.3 316.2 ± 22.3 1741.7 ± 4
48 8 9.0 ± 1.4 35.7 ± 8.1 - 896.6 ± 11
48 4 9.2 ± 2.3 37.2 ± 11.2 78.4 ± 24.8 735.0 ± 5
120 32 - - 69.0 n = 1 283.2 ±164.0 1527.2 ± 4
120 16 11.8 ± 1.8 - 87.3 ± 21.9 934.3 ± 11
120 8 9.8 ± 2.1 44.4 ± 18.6 - 820.8 ± 4
120 4 10.3 ± 0.9 - 107.2 ± 39.0 451.2 ± 8
blank - - 9.6 ± 0.4 62.4 ± 2.5 -
DLS analysis was performed on serial dilutions of a CXYG suspension (32 μg/ml) pre
analyzed directly after preparation as well as after incubation at 37°C for 48 and 12
diameter (d.) ± standard deviation (SD) in nm. Data are from six consecutively perfo
[%], respectively. The polydispersity index (PdI) of the analyzed samples is shown in
peak was detected in only one of the six performed measurements. The minus (“-“)GO and CXYG (0.2 – 100 μg/ml) under the normal assay
conditions (37°C, 30 min) (Additional file 3: Figure S2).
Fluorescence quenching
For all fluorophores (i.e. 5-CF, resorufin and NR) a dose-
dependent attenuation of fluorescence intensity was observedas function of concentration and incubation time
Relative intensity
Peak 5 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 PdI
m] d. ± SD [nm] [%] [%] [%] [%] [%]
16.8 4827.3 ± 497.5 0.0 0.0 15.1 74.1 10.7 0.7
80.9 4852.5 ± 29.0 0.2 1.4 18.7 74.4 4.3 0.9
9.3 5449.0 n = 1 9.1 3.6 12.2 74.8 0.4 0.8
6.3 5516.0 n = 1 17.9 13.2 4.6 64.0 0.3 0.7
73.2 5225.5 ± 121.0 0.0 0.0 6.9 89.3 3.7 0.5
09.2 4766.0 ± 37.6 2.4 1.3 4.8 87.2 4.4 0.7
7.5 5134.0 n = 1 9.2 7.5 0.0 83.0 0.3 0.8
9.0 - 16.0 13.7 0.8 69.6 0.0 0.6
83.5 5216.3 ± 286.8 0.0 0.1 14.3 87.7 5.4 0.6
7.7 - 3.3 0.0 7.1 88.4 0.0 0.6
0.8 5549.0 n = 1 10.8 7.6 0.0 81.4 0.3 1.0
3.8 5184.0 ± 116.8 3.2 0.0 14.7 79.9 2.1 0.6
4268.5 ± 129.9 0.0 49.6 46.9 0.0 3.5 0.5
pared in culture medium supplemented with 10% FBS. The samples were
0 h, respectively. The average hydrodynamic size is represented as mean
rmed measurements. The relative intensities of the size peaks are indicated in
the last column. “n = 1” indicates that no SD could be calculated since the
indicates that no peak could be identified at the respective dilution stage.
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the logP of the fluorophores suggesting that quenching oc-
curred through sorption of the fluorophores to GO and
CXYG. The degree of quenching caused by both graphene
derivatives was comparable. At 16 μg/ml GO, 5-CF, reso-
rufin and NR fluorescence was quenched by approximately
5, 9 and 10%. At 16 μg/ml CXYG, 5-CF, resorufin and NR
fluorescence was quenched by approximately 3, 8 and 19%,
respectively. At 32 μg/ml CXYG 5-CF, resorufin and NR
fluorescence was quenched by approximately 7, 16 and
34%, respectively. The degree of quenching was independ-
ent of the fluorophore concentration.
Cytotoxicity of GO and CXYG nanoplatelets
AlamarBlue assay
The alamarBlue assay was used to measure the metabolic
activity of the cells. Exposure of Hep G2 to GO and CXYG
for 72 h resulted in a dose-dependent increase in fluores-
cence intensity indicating an elevated metabolic activity of
these cells (Figure 4A). Although the trend was already dis-
cernible at concentrations as low as 2 μg/ml (≈ 0.6 μg/cm2),
first statistical significant differences with respect to the ve-
hicle control were only detected at concentrations startingFigure 4 Effect of GO and CXYG on Hep G2 cell viability. Hep
G2 cells were exposed to increasing concentrations of GO (grey
bars) or CXYG (dark grey bars) for 72 h. GO and CXYG suspensions
were prepared by diluting aqueous stock suspensions in medium
supplemented with 10% FBS. The vehicle control (VC) consisted of
10% (v/v) Milli-Q water in medium. Cells incubated with only
medium served as negative control (NC) (black bars). Cytotoxicity of
GO and CXYG was assessed by means of the alamarBlue assay (A),
CFDA-AM assay (B), NRU assay (C) and the fluorescamine assay (D).
Bars represent the mean and standard error of the mean (SEM) of at
least three independent repetitions. Statistically significant
differences with respect to the vehicle control (one-way rmANOVA,
Dunnett´s Post-hoc test) are indicated as followed: ⋆ p < 0.05,
⋆⋆ p < 0.01.from 8 μg/ml (p < 0.05) and 16 μg/ml (p < 0.01) of GO and
CXYG, respectively. In contrast to the observed trend,
fluorescence intensity was found to drop again when the
exposure concentration reached 32 μg/ml CXYG. No inter-
ference of GO and CXYG with the assay could be observed
in the controls that were included in the well plate.
CFDA-AM assay
The CFDA-AM assay is based on the conversion of
CFDA-AM to its fluorescent product 5-CF by cytosolic
esterases, which are only retained in cells with intact
plasma membrane. In this study a decrease in fluores-
cence intensity was observed upon 72 h exposure of
Hep G2 to increasing GO and CXYG concentrations
(Figure 4B). For both graphene derivatives statistically
significant differences (p < 0.05) compared to the vehicle
control were detected at concentrations as low as 4 μg/ml
(≈ 1.2 μg/cm2). At concentrations > 4 μg/ml means were
statistically different at a significance level of p < 0.01.
Controls that were included in the well plate did not indi-
cate any interference(s) of GO and CXYG with the assay.
Neutral red uptake assay
In the neutral red uptake assay, which is based on the ac-
cumulation of NR in functional lysosomes, a slight, albeit
not statistically significant increase in fluorescence inten-
sity was observed after 72 h exposure to GO and CXYG
(Figure 4C). Similar to the results of the alamarBlue assay
a decrease in fluorescence intensity was observed at the
highest CXYG concentration (32 μg/ml). Controls that
were included in the well plate did not indicate any inter-
ference with the assay.
Fluorescamine assay
Fluorescamine, which reacts with primary amines in
proteins, was used to measure the total protein content
in treatments and controls. No statistically significant
difference (p < 0.05) in the total protein content of the
different treatments was detected (Figure 4D).
Generation of intracellular reactive oxygen species
Both graphene derivatives induced intracellular ROS for-
mation in a dose and time dependent manner (Figure 5).
In the 24 h treatment a statistically significant increase with
respect to the control was observed at GO concentrations
of 4 μg/ml (≈ 1.2 μg/cm2) (p < 0.05) and higher (p < 0.01
for 16 μg/ml GO). After 72 h ROS levels were found to be
significantly (p < 0.01) elevated at concentrations as low as
1 μg/ml (~110% of the vehicle control) (Figure 5A). In the
24 h CXYG treatment ROS levels were significantly ele-
vated at concentrations of 8 μg/ml (≈ 2.4 μg/cm2) (p <
0.05) and higher (p < 0.01). ROS levels at 8 μg/ml did not
further increase when incubated for another 48 h (104.6%
and 105.1%, after 24 and 72 h, respectively). At higher
Figure 5 Level of intracellular reactive oxygen species (ROS)
upon exposure to GO and CXYG. Hep G2 cells were exposed to
increasing concentrations of GO (A) and CXYG (B) for 24 and 72 h
(grey and black bars, respectively). Bars represent the mean of at
least three independent experiments. Error bars represent the
standard error of the mean (SEM). Statistically significant differences
with respect to the vehicle control are indicated as ⋆ and ⋆⋆ for
p < 0.05 and p < 0.01 (One-way rmANOVA, Dunnett’s Post-hoc test),
respectively. Statistical significant differences between ROS levels
measured for the same concentration at different time points (24
and 72 h) are indicated as α (p < 0.05, t-test).
Figure 6 Mitochondrial membrane potential upon exposure to
GO and CXYG. Hep G2 cells were exposed to increasing
concentrations of GO (grey bars) or CXYG (dark grey bars) for 72 h.
GO and CXYG suspensions were prepared by diluting aqueous stock
suspensions in medium supplemented with 10% FBS. The vehicle
control (VC) consisted of 10% (v/v) Milli-Q water in medium. Cells
incubated with only medium served as negative control (NC) (black
bars). FCCP (20 μM, 10 min) was used as positive control (PC) (white
bar). Bars represent the mean and standard error of the mean (SEM)
of three independent repetitions. Statistically significant differences
with respect to the vehicle control (one-way rmANOVA, Dunnett´s
Post-hoc test) are indicated as followed: ⋆ p < 0.05, ⋆⋆ p < 0.01.
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respectively), however, a statistically significant (p < 0.01)
increase was observed: ROS levels in cells exposed to
32 μg/ml were about 60% higher than those measured in
non-treated cells and about 40% higher than those mea-
sured at the same concentration after 24 h (Figure 5B).
Effect of GO and CXYG on mitochondrial membrane
potential
In the MMP-assay statistically significant lower fluor-
escence intensities were measured in cells that were
treated for 72 h with GO or CXYG concentrations ≥8 μg/ml (p < 0.05 for 8 μg/ml CXYG, p < 0.01 for con-
centrations > 8 μg/ml CXYG and p < 0.01 for con-
centrations ≥ 8 μg/m GO). The fluorescence intensity
of the 32 μg/ml CXYG treatment reached levels com-
parable to those measured in the TCCP positive con-
trol (Figure 6).
Interaction of GO and CXYG nanoplatelets with the
cell surface
Non-treated Hep G2 cells demonstrated numerous
microvilli protruding from the cell surface (Figure 7A
and B). The surface of cells treated with 16 μg/ml
(≈ 4.2 μg/cm2) GO and 32 μg/ml (≈ 8.4 μg/cm2) CXYG
for 24 h were completely covered with GO and CXYG
(Figure 7C and D, respectively) (Note: This layer was
not discernible in the light microscope). At concen-
trations of 8 μg/ml and lower only a part of the cell sur-
face was covered with graphene platelets (Figure 7E
and F). While the micro-sized platelets were retained
by the microvilli, the nano-sized platelets were ob-
served to deposit onto the plane, i.e. microvilli-free plasma
membrane domains (Figure 7G and H, respectively). SEM
micrographs of cell cultures exposed to high GO and
CXYG concentrations for 72 h demonstrated cells with
altered cell morphology and an augmented number of
apoptotic cells (Additional file 4: Figure S1).
Figure 7 SEM micrographs of Hep G2 cells after exposure to
GO and CXYG for 24 h. Images A and B show SEM micrographs of
non-treated cells at 1500X and 5000X magnification. The scale bars in
these images correspond to 10 and 3 μm, respectively. Control-cells
demonstrated healthy cell morphology with numerous microvilli
protruding from the cell surface. Images C and D show SEM
micrographs of cells treated with 16 μg/ml GO and 32 μg/ml CXYG,
respectively. GO and CXYG platelets deposited and formed a layer
completely covering the cell surface. The scale bar displayed in C and
D corresponds to 3 and 2 μm, respectively. Images E and F show SEM
micrographs of cells treated with of 8 μg/ml GO and CXYG,
respectively. At this concentration cells were only partly covered with
nanomaterial. The scale bars in E and F correspond to 3 μm. The
boxed-in areas (white, dotted line) are shown at higher magnification
in images G and F, respectively. Image E shows the interaction of
micro-sized GO platelets (white arrows) with microvilli. Image F shows
the interaction of CXYG nanoplatelets with lateral dimensions between
approximately 200 and 400 nm with the plasma membrane (white
arrows). The scale bar in G and H is 0.8 and 0.4 μm, respectively.
Figure 8 Interaction of GO nanoplatelets with the plasma
membrane of Hep G2 cells. A) SEM micrograph showing the
interaction of GO nanoplatelets (exemplarily indicated by black
arrows) with the plasma membrane (pm) and microvilli (mv). B) SEM
micrographs showing the boxed-in area in A at higher magnification.
GO nanoplatelet penetrating the plasma membrane (arrow with white
asterisk). C) Membrane invagination (white arrow) at the site of
interaction of a GO nanoplatelet (black arrow) with the plasma
membrane. D) Disruption of the plasma membrane (black asterisk) at
the site of interaction with GO nanoplatelets (exemplarily indicated by
black arrows). Scale bars represent 200 nm in A and B, and 500 nm in
C and D. Black arrows exemplarily indicate GO nanoplatelets. mt:
mitochondrion, pm: plasma membrane, mv: microvilli.
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and intracellular fate of GO and CXYG nanoplatelets
In TEM micrographs of ultrathin sections of GO and
CXYG-treated cells numerous nanoplatelets were observed
in adjacency to the cell surface (Figures 8 and 9). The
nanoplatelets had a lateral dimension of approximately 100to 300 nm. Nanoplatelets with lateral dimensions bigger
than 500 nm were sparse. On some occasions the inter-
action of the nanoplatelets with the plasma membrane led
to the formation of membrane invaginations (Figures 8C
and 9B). However no uptake of nanoplatelets into endo-
cytotic vesicles could be observed.
GO and CXYG nanoplatelets were found to pierce
through and mechanically disrupt the plasma membrane
(Figures 8B, 9C and D). At some of the sites where the
nanoplatelets interacted with or penetrated through
the plasma membrane, highly-organized fibrillar struc-
tures resembling intermediate filament bundles (com-
pare [55,56]) were observed (Figure 9C and D). TEM
images provided evidence that both graphene derivatives
crossed the plasma membrane and accumulated inside
the cell (Figures 10 and 11). GO and CXYG were pre-
sent as individual nanoplatelets (Figure 10A) or as
aggregate-like structures of different size and compact-
ness (Figure 10D, E and G, Figure 11A, E and G). The
aggregates were either freely-localized in the cytosol
(Figure 10D) or enveloped within a membrane (Figure 10F
and G, Figure 11A, B and E-G) and observed as early
as 24 h after cell treatment. TEM micrographs taken at
high magnification demonstrated the laminated charac-
ter of the aggregated material (Figures 10H and 11D).
Figure 9 Interaction CXYG nanoplatelets with the plasma
membrane. (A) SEM micrograph showing the interaction of CXYG
nanoplatelets (exemplarily indicated by black arrows) with the
plasma membrane (pm) and microvilli (mv). (B) Vesicle formation
(white arrow) at the site of interaction of CXYG nanoplatelets (black
arrow) with the plasma membrane. (C) and (D) CXYG nanoplatelets
(black arrows) interacting with the plasma membrane and
penetrating the latter (C) leading to plasma membrane disruption
(the site of disruption is indicated with a white asterisk). Thick
intermediate filament bundles (if) are present at the site of injury.
Scale bars represent 500 nm in (A) and (D), and 200 nm in (B) and
(C). Other cellular structures indicated in Figure nine: lp: lipids,
ly: lysosomes.
Figure 10 Intracellular fate of GO nanoplatelets. A) GO
nanoplatelet freely localized (black arrow) in the cytoplasm. B)
Degraded mitochondria (mt #). C) Interaction of a GO nanoplatelet
(black arrow) with a lysosome (ly). For comparative purposes
extracellular GO nanoplatelets are highlighted (black arrows). D)
Interaction of cytosolic GO nanoplatelets with a mitochondrion (mt).
E) Intracellular aggregation of GO nanoplatelets (black arrows with
asterisks). F) High-magnification image of the boxed-in area in E
showing a vesicle with GO nanoplatelet aggregates and degraded
cell organelles. GO nanoplatelets (inside and outside the cell) are
exemplarily indicated with black arrows. G) Phagosome-like vesicle
with aggregates of GO nanoplatelets (arrow with asterisk) in close
proximity to mitochondria (mt). H) High-magnification image
(250000X) of the boxed-in area in G showing the laminar nature of
the enclosed material (black arrow). Scale bars are 200 nm in A,
500 nm in B, C, D and F, 2 μm in E and G, and 100 nm in H.
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containing vesicle with an intracellular vacuole (Figure 11E
and F). Moreover, on some occasions, GO and CXYG
aggregates were surrounded by thick intermediate fila-
ment bundles (Figure 11G). Interaction of cytosolic nano-
platelets with cell organelles such as lysosomes or mito
chondria was also observed (Figure 10D and E, respect-
ively). Furthermore, GO and CXYG-treated cells demon-
strated increased mitochondrial calcium accumulation
(Figures 10D and 11E), an augmented number of auto-
phagosomes and degraded mitochondria (exemplarily
represented in Figure 10B), as well as alterations in chro-
matin structure.
Discussion
The cytotoxic potential of GO and CXYG nanoplatelets
was assessed in the human hepatoma cell line Hep G2
by means of various cell viability assays based on differ-
ent toxicity endpoints.
In the CFDA-AM assay both graphene derivatives
caused a dose-dependent decrease in fluorescence inten-
sity. According to the assay principle a decrease in fluores-
cence intensity in the CFDA-AM assay may be indicative
of various cytotoxic effects including plasma membrane
damage, cell proliferation inhibition and cell death. How-
ever, observation in the light microscope and measurementof total protein contents did not disclose any significant
differences in the amount of cells in treatments and con-
trols. This suggests that the decrease in fluorescence
reflected primarily plasma membrane damage.
Yet, attention must be paid to possible interference of
GO and CXYG with the assay. Both graphene derivatives
were able to act as fluorescence quenchers. However,
considering that the nanomaterial-containing medium
was entirely removed prior to adding the probe, the
Figure 11 Intracellular fate of CXYG nanoplatelets. Images A, B, C
and D show SEM micrographs of an intracellular CXYG nanoplatelets
aggregation (black arrow with asterisk) at different magnifications (50 k,
250 k, 300 k and 400 k X, respectively). The boxed-in areas indicate the
part of the image that was amplified in the image of next higher
magnification, respectively. Image E shows the interaction of an
intracellular CXYG aggregation (black asterisk) with a vacuole (v). The
site of interaction between the two compartments is represented at
higher magnification in F. Image G shows two intracellular CXYG
aggregates (black asterisk) in close proximity to each other and
surrounded by intermediate filament bundles (if). H shows the
ultrastructure of a cell exposed to CXYG for 72 h. The black asterisk
indicates the site of CXYG accumulation. The scale bar displayed in A
and H corresponds to 2 μm. The scale bars in B and H are 500 nm. The
scale bars represented in C and D correspond to 100 nm. The scale bar
in E and G is 1 μm. Other cellular structures indicated in Figure 11 are
indicated as followed: pm: plasma membrane, nc: nucleus, mt:
mitochondrion, lp: lipid, v: intracellular vacuole.
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was probably much lower than the concentration at
which a relevant degree of quenching was observed. Fur-
thermore, it was observed that despite the high colloidal
stability of the suspensions GO and CXYG platelets
deposited on the plasma membrane forming a layer,
which completely covered the cells’ surface at exposureconcentrations ≥ 16 μg/ml (≈ 4.2 μg/cm2). The presence
of such a layer may locally quench the fluorescence and/
or prevent the uptake of CFDA-AM into the cells due to
steric, electrostatic or chemical interaction with the
probe so that cells would show lower fluorescence inten-
sity, independent of whether or not their plasma mem-
brane is damaged. However, in preliminary experiments
in which three different hepatoma cell lines (Hep G2,
H4IIE and RTH149) were treated with the same gra-
phene suspension only Hep G2 cells demonstrated a de-
crease in fluorescence intensity (Additional file 4: Figure
S2). This suggests that the observed effect was not due
to interference as if this was the case all cell lines would
show a similar trend. Moreover, at the lower concentra-
tions at which membrane damage was observed (4 and
8 μg/ml) only a small area of the cell surface was
covered with nanomaterial, so that it is unlikely that
CFDA-AM diffusion over the cellular membrane was
significantly impeded. Yet, the implications for assays that
are based on measuring the leakage of cellular macromol-
ecules (e.g. lactate dehydrogenase (LDH) or mRNA) into
the medium may be more important than for assays using
fluorescent probes of low molecular weight and thus have
to be further investigated.
Plasma membrane damage can be the consequence of
various cytotoxic effects. The results obtained in this
study suggest that the observed loss in plasma mem-
brane structural integrity was associated with a strong
physical interaction of GO and CXYG nanoplatelets with
the phospholipid bilayer. TEM micrographs of ultrathin
sections demonstrated that GO and CXYG nanoplatelets
were able to penetrate through the plasma membrane
resulting in disruption of the phospholipid bilayer. If the
capability of the nanoplatelets to penetrate through the
plasma membrane depended on their relative orientation
to the latter has to be further examined. Cells responded
with the formation of thick intermediate filament bundles,
most likely to countervail the tensile forces occurring at
the site of interaction/disruption and thus mechanically
enforce the plasma membrane and prevent further loss of
structural integrity [57-59].
Graphene nanomaterials-caused plasma membrane dam-
age has been reported previously, in both prokaryotic
[41,60] and eukaryotic cells [13,38,39,42,43,45]. Liao et al.
(2012) demonstrated that both pristine graphene and GO
sheets were able to disrupt the plasma membrane of eryth-
rocytes (hemolysis assay).The EC50 calculated for the
hemolytic activity of GO platelets with similar dimensions
to those used in our study was 30.5 μg/ml (after 3 h of in-
cubation with agitation) [43]. Chang et al. (2010), on the
contrary, were not able to observe any adverse effect of GO
nanoplatelets with lateral dimensions of about 200, 400 and
800 nm on plasma membrane integrity in the human lung
cell line A459. In fact, at exposure concentrations ≥ 50 μg/
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the control [45]. In a study by Sasidharan et al. (2011), in
which carboxyl-functionalized graphene was compared
with pristine graphene, no LDH leakage could be observed
neither - even at concentrations as high as 300 μg/ml [38].
Zhang et al. (2010) observed that graphene aggregates/ag-
glomerates that had sedimented onto the surface of rat
PC12 cells caused an increase in LDH leakage only at the
highest exposure concentration (100 μg/ml) [42]. These
findings are partly conflicting with those obtained in our
study. However, the LDH assay may not be the most ap-
propriate one to assess the membrane disrupting potential
of graphene nanomaterials. First, as discussed above, a
graphene layer covering the cell surface may impede leak-
age of LDH into the medium. And second, any enzyme
“successfully” released into the medium may adsorb to the
suspended nanomaterial and thus be inactivated.
The observed effect of GO and CXYG on plasma mem-
brane integrity was congruent with the concentration-
dependent increase in alamarBlue reduction that was
observed upon exposure. Although the exact mechanism
through which alamarBlue is reduced still has to be eluci-
dated, it is generally assumed that reduction occurs in the
mitochondria. There, due to its relatively less negative
redox potential, it can receive electrons from various
components of the electron transport chain including
NADPH, NADH, FADH2, FMNH2, and cytochromes
[61]. As a consequence, an increase in resazurine reduc-
tion could be indicative of an increase in the metabolic ac-
tivity of the cells and/or an increase in cell number [61].
Since no significant differences in the protein content of
treated and not-treated wells were observed, the increased
resazurine reduction could well be related with an aug-
mented metabolic activity of the individual cells. The in-
verse correlation of metabolic activity and degree of
membrane damage may suggest that cells have initiated
energy-dependent processes involved in plasma mem-
brane repair (e.g. rearrangement of cytoskeletal elements,
biosynthesis of proteins and lipids, trafficking of exocytotic
vesicles to injured sites at the plasma membrane) [62].
The increase in fluorescence observed in the alamarBlue
assay could also be due to interference or autofluorescence
properties of the graphene derivatives used in this study.
However, neither acellular alamarBlue reduction by GO
and CXYG nor autofluorescence at the excitation and
emission wavelength used could be observed. Besides, in-
cubation of resorufin (=the fluorescent reduction product
of alamarBlue) with increasing concentrations of GO and
CXYG demonstrated that both graphene derivatives were
able to quench its fluorescence. Thus, interference of the
tested nanomaterials with the assay would rather lead to
an underestimation of the signal.
It must also be kept in mind that resazurine can be re-
duced by mechanisms different to those stated above.Gonzalez and Tarloff (2001), for example, demonstrated
that resazurine can be reduced by cytosolic and micro-
somal enzymes (S9-fraction) [63]. Thus, an increased ex-
pression/activity of the latter, as it is for example
observed during detoxification, could also explain the in-
crease in fluorescence intensity. Besides, Lancaster et al.
(1996) suggested that resazurine reduction may occur
through scavenging of electrons from lipid peroxidation
cascades in dying cells [61,64] and Prutz et al. (1996) dem-
onstrated that resazurine reduction may occur through re-
action with free radicals [65]. Since in our study
resazurine reduction was correlated with intracellular ROS
levels, these mechanisms could also explain the elevated
fluorescence intensity at high exposure concentrations.
Induction of oxidative stress is considered one of the
principal mechanisms underlying nanomaterial toxicity
[66,67]. In our study, GO and CXYG nanoplatelets were
observed to induce the generation of intracellular ROS in
a concentration and time-dependent manner. In addition,
GO and CXYG-induced ROS formation seemed to follow
different kinetics. For GO, maximum ROS levels were
reached after exposure to 16 μg/ml for 24 h. In cells
treated with lower GO concentrations (1 – 8 μg/ml) intra-
cellular ROS levels kept increasing in the lapse between 24
and 72 h and eventually reached levels comparable to
those measured at 16 μg/ml. On the contrary, exposure to
low concentrations of CXYG (< 8 μg/ml) did not result in
significantly increased ROS levels (not even upon expos-
ure for 72 h). Yet, ROS levels in cells treated with high
CXYG concentrations (≥ 8 μg/ml) were observed to in-
crease considerably in the lapse between 24 and 72 h.
Regarding the oxidant-generating potential of GO, the
obtained results are consistent with those reported by
other authors. As in the present study, Yuan et al. (2012)
could not detect any significant increase in intracellular
ROS levels in Hep G2 cells exposed to 1 μg/ml of single-
layered GO for periods of less than 24 h [47]. Yet, the
results presented here demonstrate that exposure to
such low concentrations can indeed lead to intracellular
ROS formation in this cell line if the exposure duration
exceeds 24 h. The ability of GO to induce the generation
of intracellular ROS was also assessed in other cell lines.
A549 cells exposed to 10 μg/ml GO for 24 h demon-
strated comparable ROS levels to those determined in
this study [45]. In human skin fibroblasts, however, no
significant increase with respect to the control could be
detected after 24 h of exposure to concentrations as high
as 25 μg/ml [43]. The discrepancy between the results
obtained in this study and those stated above (including
ours) might be due to differences in the lateral size of
the platelets tested (> 1 μm), the suspension protocol
(serum-free medium), the assay protocol (loading of the
cells with the dye DCFH-DA was carried out prior to
treatment) or the sensitivity of the cell line. To our
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CXYG have been reported in the scientific literature to
this day.
The fact that GO and CXYG-induced ROS generation
displayed different kinetics suggests that the underlying
ROS-generating mechanisms are distinct. The exact
mechanism(s) through which a nanomaterial exerts oxi-
dative stress is relatively difficult to identify and still re-
mains to be elucidated for most nanomaterials including
graphene and graphene derivative nanoplatelets. An in-
tegrative consideration of results obtained by different
assays, however, can help to get a first indication about
the possible mechanisms involved. In general, it is distin-
guished between direct and indirect mechanisms of ROS
generation. Direct ROS generation typically involves
processes that are independent of the presence of bio-
logical systems (acellular ROS generation), i.e. are solely
a function of the nanomaterial’s physico-chemical prop-
erties. Indirect ROS generation, on the contrary, typic-
ally involves cellular (i.e. biochemical) processes that
were triggered by the nanomaterial beforehand [68]. In
non-inflammatory cells, one of the probably most im-
portant nanomaterial-triggered mechanisms leading to
increased intracellular ROS formation is impairment of
mitochondrial function. To assess whether or not the in-
creased ROS levels may have originated from GO- and
CXYG-induced alterations in mitochondrial processes,
the nanomaterials´ effect on the mitochondrial integrity
was investigated. It was observed that exposure to GO
and CXYG nanoplatelets resulted in a decrease in fluor-
escence intensity in the MMP assay indicating mi-
tochondrial membrane depolarization and/or a decrease
in the amount of (functional) mitochondria. These find-
ings are consistent with those of Li et al. (2012), who
reported that the MMP decreased in a dose and time-
dependent manner in the macrophage cell line RAW
264.7 exposed to increasing concentrations of pristine
graphene [44]. Depolarization of the mitochondrial
membrane can be due to the loss of both structural and
functional integrity of the mitochondrion [69]. Mito-
chondrial dysfunction is known to be associated with
oxidative damage of mitochondrial macromolecules in-
cluding mtDNA, lipids and proteins caused by reaction
with intracellular ROS [69]. Structural damage of mito-
chondria can be provoked directly, i.e. by physical inter-
action of the nanomaterial with the mitochondrial
membrane [70] or indirectly, e.g. by physically disrupting
the membrane of other cell organelles, such as lyso-
somes, resulting in release of hydrolytic enzymes into
the cytosol [71].
Both mechanisms would require prior internalization of
the nanomaterial, which in the present study was ob-
served. In a few cases interaction of the nanoplatelets with
the plasma membrane was observed to be attended byinvagination of the latter. Dutta et al. (2007) demonstrated
that serum albumin adsorbed to the surface of carbon
nanotubes facilitates their uptake via scavenger receptor-
mediated endocytosis [72]. Interaction of scavenger re-
ceptors in the plasma membrane of Hep G2 with serum
proteins adsorbed to the surface of GO and CXYG
nanoplatelets may explain the observed membrane in-
vagination at the site of platelet/membrane interaction.
However, in this study no evidence for successful uptake
of GO or CXYG into endocytotic vesicles was found.
TEM micrographs demonstrated that GO and CXYG
nanoplatelets were able to penetrate through the plasma
membrane and were freely localized in the cytosol. Be-
sides, TEM images showed aggregates of different size
and compactness, whereas most (but not all) were en-
veloped by intracellular membranes. This suggests that
GO and CXYG nanoplatelets that entered the cytosol
were recognized by the cell as foreign particle, concen-
trated in one or more defined areas in the cytosol and
then packed into intracellular vesicles to isolate the
nanomaterial and protect itself from further damage.
Yet, in an initial phase of the internalization process
GO and CXYG nanoplatelets and aggregates were freely
localized in the cytosol and thus potentially able to dir-
ectly interact with cellular organelles including mito-
chondria and lysosomes. In the present work no direct
interaction of individual nanoplatelets with lysosomes
could be observed. In addition, no adverse effect of GO
and CXYG nanoplatelets on lysosomal function was
detected in the NRU assay. All these results together
suggest that GO and CXYG nanoplatelet-induced ROS
generation and mitochondrial damage were not related
with release of lysosomal iron or hydrolytic enzymes into
the cytosol.
Direct interaction of GO and CXYG nanoplatelets
with mitochondria could be observed in one micrograph.
Moreover, GO and CXYG-treated cells demonstrated an
augmented number of autophagosomes, in some of which
degraded mitochondria could be identified. Degraded mi-
tochondria could also be observed in the cytosol, i.e. not
yet enclosed in autophagocytotic vesicles. Thus, it may be
possible that enhanced intracellular ROS levels ori-
ginated from mitochondrial damage. If mitochondrial
damage was caused by physical interaction of GO and
CXYG nanoplatelets with the mitochondrial membrane
or is a secondary effect of a possible oxidative damage
of mitochondrial macromolecules due to elevated intra-
cellular ROS levels remains to be elucidated [70,73].
So far, uptake of graphene nanomaterials has been al-
most exclusively reported for phagocytotic cells [13,40,44].
To our knowledge, there is only one published study
reporting accumulation of a graphene nanomaterial in the
cytosol of a non-phagocytotic cell line [38]. Yue et al.
(2012), who studied the uptake of GO in four hepatoma
Figure 12 Hypothetic model of graphene nanomaterial
internalization and cytotoxicity. GO and CXYG nanoplatelets
penetrate through the plasma membrane into the cytosol, are
concentrated and encapsulated in intracellular vesicles. Cells
respond with the formation of cytokeratin filament bundles to
mechanically reinforce the plasma membrane and initiate plasma
membrane repair mechanisms. These processes involve an increase
in metabolic activity. Exposure to GO and CXYG nanoplatelets results
in elevated intracellular ROS levels, perturbation of mitochondrial
structure and function, and an augmented number
of autophagosomes.
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alization. They suggested that the negative surface charge
of GO may have led to electrostatic repulsion of the plate-
lets from the plasma membrane [40]. The SEM micro-
graphs in the present study however demonstrate that GO
and CXYG have a rather high affinity to biological
membranes. These findings suggest that other physico-
chemical properties may determine whether graphene
nanomaterials are internalized and that further research
has to be carried out into this direction.
Conclusions
In this study it was demonstrated that ultrasonication
followed by a centrifugation step yields stable stock sus-
pensions. The suspension protocol may be used to pro-
duce stock suspension of other commercially available
graphene derivatives similar to the ones used in this
study. For cell culture experiments serum-supplemented
medium should be used as in serum-free medium rapid
flocculation and sedimentation of the nanomaterial
occurs. Yet, as demonstrated by the SEM micrographs,
also when working with stable suspensions graphene
nanoplatelets may still adsorb onto the cell surface. In
the present study it was observed that cells exposed to
GO and CXYG concentrations of 16 μg/ml for 24 h
were completely covered with nanomaterial. Thus, when
assessing the cytotoxicity of graphene nanomaterials the
exposure concentrations should not exceed those used
in this study as the local exposure concentration is
already maximal. Any further increase in the concentra-
tion may cause nanomaterial-unspecific cell damage due
to mechanical stress and/or increase the probability of
interference of the nanomaterial with the assay. In this
study, first cytotoxic effects were observed at concentra-
tions as low as 4 μg/ml. Among the modes of action
assessed, plasma membrane damage and induction of
oxidative stress appeared to play a crucial role. More-
over, GO and CXYG nanoplatelets were able to pierce
through the plasma membrane and enter the cytosol,
Cells were able to successfully isolate the nanomaterial
by enclosing it in intracellular vesicles (a summary illus-
tration with a hypothetic model of graphene nano-
material internalization and cytotoxicity is shown in
Figure 12). Graphene derivative nanomaterials may thus
represent an attractive platform for biomedical applica-
tions such as drug carriers. Yet, due to the sparse
in vitro and in vivo toxicological data and indications
that graphene nanoplatelets may accumulate in various
organs including lungs, liver, spleen and kidney and
may not easily be cleared from the body [74], further re-
search has to be carried out to identify the physico-
chemical properties that determine their toxicity and
ways to enhance its biocompatibility and performance
for use in biomedical applications.Methods
Nanomaterials
Single-layer Graphene oxide (GO) and Carboxyl gra-
phene (CXYG) were purchased from ACS Material,
LLC. (Ames, IA, USA). GO was prepared by modified
Hummers´s method and exfoliated as described in
Allister et al. (2007) and supplied as thin film with a sin-
gle layer ratio of ~ 99% [75]. The weight content in car-
bon and oxygen was 51.26% and 40.78%, respectively
(C/O ratio: 1.67). CXYG was supplied as dry powder.
The weight content in carbon and oxygen was 50.36%
and 42.23%, respectively (C/O ratio: 1.59). The carboxyl
ratio was 5%. Both graphene derivatives had a purity of
approximately 99%.
Chemicals and cell culture products
Cell culture: Ultraglutamine 1 (200 mM) (L-Gln), fetal bo-
vine serum (FBS), penicillin and streptomycin (P/S) (10 000
U/ml / 10 mg/ml), non-essential amino acids (NEAA)
100X, Trypsin EDTA (200 mg/l EDTA, 17 000U trypsin/L),
cell culture EMEM (Eagle’s Minimum Essential Medium)
was sourced from Lonza (Barcelona, ES). Phenol red-free
Minimum Essential Medium (MEM) was purchased from
PAN-Biotech (Aidenbach, DE).
Assay reagents and chemicals: AlamarBlue and 5-
carboxyfluorescein diacetate, acetoxy methyl ester (CFDA-
AM) were purchased from Life Technologies (Madrid, ES).
Neutral red (3-amino-7-dimethylamino-2-methylphenan-
zine hydrochloride) solution (0.33%), 6-carboxy-2′7′-
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rescein (5-CF), resorufin, fluorescamine, chloramine-T
trihydrate, sodium dodecyl sulfate (SDS) and bovine
serum albumin (BSA) were sourced from Sigma-Aldrich
(Madrid, ES).
Solvents, fixatives and resin: 2-propanol, acetonitrile,
acetone and glacial acetic acid were purchased from
Sigma-Aldrich (Madrid, ES). Ethanol was from Panreac
(Barcelona, ES). Paraformaldehyde (16%) was sourced
from Electron Microscopy Sciences (Hatfiled, UK), glu-
taraldehyde (25%), osmium tetroxide (2%) and Spurr’s
resin were purchased from TAAB Laboratories Equip-
ment Ltd (Aldermaston, UK). High grade purity water
(> 18 MΩ cm-1) was obtained from a Milli-Q Element
A10 Century (Millipore Iberia, ES).
Characterization
Preparation of GO and CXYG stock suspensions
GO and CXYG stock suspensions were prepared in
sterile, 10 ml Pyrex glass tubes (SciLabware Ltd.,
Stone, UK). First, GO and CXYG were dispersed
in sterile Milli-Q water at a concentration of 1 mg/
ml by means of ultrasonication at 37 kHz for 2 h in a
4.25 L bath-type ultrasonic cleaner unit (Elmasonic S
40/(H), Elma GmbH & Co. KG, Singen, DE). Fol-
lowing sonication the suspensions were centrifuged
at 1300 g for 30 min (Lince R, Orto Alresa, Madrid,
ES) and the supernatants transferred to a fresh Pyrex
glass tube. The concentration of the supernatants
was estimated by means of a concentration-absorb-
ance standard curve generated from aliquots of the
original, i.e. not centrifuged stock suspensions. Serial
dilutions and absorbance measurements were per-
formed in 96-well plates and a microplate reader
(Tecan Genios, Tecan Group Ltd., Männedorf, CH)
equipped with a 340 nm filter, respectively. The con-
centration of the centrifuged CXYG suspension was
adjusted to 320 μg/ml. The concentration of the GO
suspension was adjusted to the next lower dilution
stage (160 μg/ml) as its concentration was below
320 μg/ml after centrifugation.
Dynamic light scattering
The hydrodynamic size of GO and CXYG in both the
stock suspension and the culture medium was de-
termined by means of dynamic light scattering (DLS)
analysis using a Zetasizer Nano-ZS apparatus (Malvern
Instruments Ltd., Malvern, UK). Milli-Q water and cul-
ture medium were used as background controls. At least
four measurements were taken of each sample. The
number of runs per measurement, the attenuator and
the optimal measurement position were automatically
determined. Data were analyzed using Zetasizer Software
version 6.34 (Malvern Instruments Ltd.).ζ-Potential measurements
ζ-potential measurements were performed using dispos-
able capillary cuvettes (Malvern Instruments Ltd., UK)
and a Zetasizer Nano-ZS apparatus (Malvern Instruments
Ltd., Malvern UK). Four measurements were taken of each
sample. The number of runs was set automatically.
Atomic force microscopy
Aliquots (25 μl) of diluted GO and CXYG stock suspen-
sions (final concentration: 12.5 - 25 μg/ml) were trans-
ferred onto freshly exfoliated mica substrates and air-dried
at room temperature overnight. Atomic force microscopy
(AFM) imaging of the dried samples were performed in
tapping mode on a Nanoscope IIIa Mulitmode apparatus
(Veeco, Plainview, NY, USA) using a TESP-SS cantilever
with a tip radius of 2 nm and a spring constant of 42 N ·
m-1 (Veeco). Height and phase images were recorded sim-
ultaneously. Images were analyzed using NanoScope soft-
ware version 6.24r1 (Veeco). Measurements of the lateral
dimension of the nanoplatelets were performed on AFM
topographical images converted to 8-bit format and
tresholded using ImageJ version 1.34u (Wayne Rasband,
National Institutes of Health, USA).
Transmission electron microscopy
Transmission electron microscopy (TEM) was per-
formed to morphologically characterize the GO and
CXYG platelets dispersed in the stock suspensions.
Carbon-coated copper grids were drop-coated with the
stock suspensions. TEM analysis was carried out using a
JEOL 2100 HT (JEOL Ltd., Tokyo, JP) operated at an ac-
celerating voltage of 200 kV.
Preparation of GO and CXYG suspensions in culture
medium
For cell culture studies the aqueous stock suspensions had
to be diluted in culture medium. The composition of the
culture medium is known to have an important influence
on the colloidal stability and biological activity of nano-
materials. Therefore it was investigated how the medium
supplements influence the stability of GO and CXYG. For
this purpose, GO and CXYG stock suspensions were di-
luted 1:10 in three different complex culture media:
MEM, MEM supplemented with 1% L-Gln and 1% P/S,
and MEM supplemented with 1% L-Gln, 1% P/S and 10%
FBS, respectively. The stability of the suspension was
assessed by means of DLS and visual observation.
Routine cell culture
The human hepatocellular carcinoma cell line Hep G2
was obtained from the American Type Culture Col-
lection (ATTC) (Manassas, VA, USA). Hep G2 cells
were cultured in 75 cm2 Cell Star cell culture flasks
(Greiner Bio-One GmbH, Frickenhausen, DE) in EMEM
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and 10% FBS. The flasks were incubated at 37°C in a hu-
midified 5% CO2 atmosphere and split twice a week using
PBS/EDTA and trypsin.
Cytotoxicity
The toxicity of graphene oxide (GO) and carboxyl
graphene (CXYG) nanoplatelets towards the human hepa-
toma cell line Hep G2 was assessed using various cytotox-
icity assays based on different toxicological endpoints
(metabolic activity, cell membrane disruption, lysosomal
integrity, total protein content). The seeding and exposure
protocol was similar for all 96-well plate-based cytotox-
icity assays (CFDA-AM assay, alamarBlue assay, neutral
red uptake (NRU) assay, fluorescamine assay).
Exposure
Hep G2 cells were seeded into transparent, flat-bottom
96-well plates (growth area: 0.34 cm2) (Greiner Bio-One
GmbH, Frickenhausen, DE) by adding 100 μl of cell sus-
pension (7.5 × 105 cells/ml) to each well. After seeding
the well plates were incubated at 37°C in a humidified
5% CO2 atmosphere for 24 h. GO and CXYG stock sus-
pensions (160 and 320 μg/ml, respectively) were diluted
1:10 in phenol red-free MEM supplemented with 1%
L-Gln, 1% P/S and 10% FBS (in the following text
referred to as MEM+) and applied to the cell culture
plate in which serial dilutions (dilution factor of 2) were
performed. As a positive control, a subset of wells was
treated with increasing concentrations of SDS (0.02 mM –
0.5 mM, dilution factor 1.5). Cells treated with phenol
red-free MEM+ served as negative control. Cells treated
with 10% (v/v) Milli-Q water/phenol red-free MEM+
served as vehicle control. The microwell plates were incu-
bated at 37°C in a humidified CO2 atmosphere for 72 h
and then subject to analysis.
AlamarBlue, CFDA-AM and Neutral Red Uptake assay
The alamarBlue, CFDA-AM and NRU assay were per-
formed on the same set of cells. The assays were con-
ducted following a modified version of the protocol
described by Dayeh et al. (2005) [76]. Prior to adding the
probes the exposure medium was removed and the cells
rinsed twice with 200 μl PBS. Then, 100 μl serum- and
phenol red-free MEM containing 1.25% (v/v) alamarBlue
and 4 μM CFDA-AM was added to each well. The 96-
well plates were incubated for 30 min in the dark at 37°C
and 5% CO2. Subsequently the fluorescence intensity was
measured at excitation and emission wavelengths of 532
and 590 nm (resorufin) or 485 and 535 nm (5-CF), re-
spectively, using a microplate reader (Tecan Genios,
Tecan Group Ltd., Männedorf, CH). Subsequently, the
medium was removed and the cells were washed once
with PBS. 100 μl of NR solution (0.03 mg/ml in phenolred-free MEM) were added per well and the plates incu-
bated for 1 h in the dark at 37°C in a humidified 5% CO2
atmosphere. After the incubation period the NR solution
was removed, the cells rinsed twice with 200 μl PBS and
the NR retained in the cells extracted with an acidified
(1% glacial acetic acid) 50% ethanol/49% Milli-Q water so-
lution (150 μl/well). NR fluorescence was measured at
532 nm/680 nm (excitation/emission) using a microplate
reader (Tecan Genios). The fluorescent values were
corrected for the cell-free control and normalized against
the medium control.
Fluorescamine assay
After exposure, the GO and CXYG-containing medium
was discarded and the cells rinsed twice with PBS. The
well plates were immediately frozen using liquid nitro-
gen and then stored at −20°C for 1 h. Then, 75 μl of
PBS and 75 μl of fluorescamine solution (0.15 mg/ml
fluorescamine in acetonitrile) was added to each well
and the plates placed on a horizontal shaker for 15 min
in the dark. Subsequently, the fluorescence intensity
was measured using a Tecan Genios microplate reader
equipped with a 360 nm excitation and 450 nm emis-
sion filter, respectively. The fluorescent values were
corrected for the cell-free control and normalized against
the medium control.
Interference
In the cytotoxicity assays two different interference con-
trols were included. To assess if GO and CXYG ad-
sorbed to the polystyrene surface of the culture well may
interfere with the assay cell-free wells were treated with
the highest exposure concentration. Non-treated cell-
free wells served as reference. To assess if GO and
CXYG adsorbed to the cell monolayer may interfere
with or contribute to the fluorescence signal intensity at
the excitation and emission wavelengths used, cells were
treated with the highest exposure concentration but no
probe was added at time of analysis. Non-treated cells to
which no dye was added served as reference. In addition,
prior to performing the cytotoxicity assays, it was assessed
if the tested nanomaterials interfere with the assay reagents
or their fluorescent conversion products (see below).
Autofluorescence
Due to their aromatic nature graphene and graphene deriv-
atives are principally able to exhibit fluorescence. To assess
if the tested graphene derivatives show autofluorescence
and thus may interfere with the fluorescence-based cytotox-
icity assays used in this study three-dimensional fluores-
cence spectra of GO and CXYG stock suspensions
(10 μg/ml) were recorded using a Perkin-Elmer (Nor-
walk, CT) LS 55 luminescence spectrometer. Fluores-
cence emission was measured over a wavelength range
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sequentially increased from 250 to 600 nm by 5 nm
steps. Data were visualized in form of excitation − emis-
sion matrix plots using the software WinLab 4.00.02
(Perkin-Elmer, Inc., 2001, Norwalk, CT, USA).
Redox-interaction of GO and CXYG with assay reagents
Resazurine (7-Hydroxy-3H-phenoxazin-3-one 10-oxide),
the active compound in the commercial solution ala-
marBlue, is a redox-sensitive dye and thus able to
undergo redox (reduction-oxidation) reactions with GO
and CXYG. To assess if GO or CXYG residues retained
in the culture vessel can reduce resazurine also acel-
lularly, and thus lead to an increase in fluorescence in-
tensity independent of the metabolic activity or number
of cells, alamarBlue (1.5% (v/v) prepared in phenol red-
free medium without FBS) was incubated with increas-
ing concentrations of GO and CXYG (0.2 – 100 μg/ml)
at 37°C for 30 min (cp. alamarBlue assay protocol). Sub-
sequently the well plates were read at 532 nm/590 nm
(= excitation and emission maxima of resorufin - the
conversion product of alamarBlue) in a Tecan Genios
microplate reader.
Fluorescence quenching
Fluorescence quenching was assessed by incubating the
fluorophores that are formed in course of the CFDA-
AM , alamarBlue and neutral red (NR) uptake assay (i.e.
5-carboxyfluorescein (5-CF), resorufin and protonated
NR) with increasing concentrations of GO and CXYG
(0.2 – 100 μg/ml), respectively. The used fluorophore
concentrations corresponded to the maximal concentra-
tion that can be expected to be formed in the respective
assays (4 μM 5-CF, 1 μM resorufin, 0.03 mg/ml NR) and
to 10% of the maximal concentration that can be
expected in the assay (0.4 μM 5-CF, 0.1 μM resorufin),
respectively. 5-CF and resorufin were prepared in
serum- and phenol red-free medium (cp. CFDA-AM
and alamarBlue assay protocol). NR was diluted in 50%
ethanol, 49% Milli-Q water, 1% glacial acetic acid (= ex-
traction solution used in the NRU assay). The assay itself
was carried out as followed: GO or CXYG stock suspen-
sions (non-centrifuged) (0.1 mg/ml Milli-Q) were serially
diluted (1:2) in the respective fluorophore solutions. The
serial dilutions were performed in a 96-well plate. Fluor-
escence intensity was measured in a Tecan Genios
microplate reader using 532 nm/590 nm, 485 nm/
535 nm, and 532 nm/680 nm excitation and emission fil-
ters for resorufin, 5-CF and NR, respectively.
Generation of reactive oxygen species
Cell seeding and treatment with GO and CXYG was
performed as describe above. Cells treated with increasing
concentrations of chloramine-T trihydrate (0.04 mM –10 mM) were used as positive control. After treatment,
the microwell plates were incubated at 37°C and 5% CO2
for 24 or 72 h, thereupon the cells were rinsed twice with
PBS prewarmed to 37°C (150 μl/well). Then, 100 μl of a
20 μMDCFH-DA solution prepared in serum- and phenol
red-free MEM (=loading solution) was added to each well
and incubated for 15 min in the dark at 37°C and 5% CO2.
The loading solution was discarded and cells were washed
twice with 150 μl PBS. The increase in fluorescence inten-
sity was measured over 90 min in 15 min intervals in a
Tecan Genios microplate reader using 485 nm and
530 nm excitation and emission filters, respectively. Rela-
tive reactive oxygen species (ROS) levels were calculated
as followed:
½ ti treatment= t 0 treatment  100ð Þ‐
ðti negative control= t 0 negative control  100Þ  100
with “i” being the time at which no further increase in
fluorescence intensity was observed (typically after
60 min).
Mitochondrial membrane potential
The mitochondrial membrane potential (MMP) was
measured using the positively-charged fluorescent
dye TMRE (tetramethylrhodamine, ethyl ester), which
readily accumulates in active mitochondria. TMRE
was purchased as part of the TMRE Mitochondrial
Membrane Potential Assay Kit (Abcam, Cambridge,
UK), which also included FCCP (carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone) – an ionophore
uncoupler of oxidative phosphorylation that served as
positive control. The assay was performed according
to a protocol developed on basis of the assay pro-
cedure provided by the manufacturer. Hep G2 cells
were seeded into μClear bottom, black 96-well plates
(growth area 0.34 cm2) (Greiner Bio-One GmbH, DE)
(7.5 × 104 cells/well) and treated with GO and CXYG
as described in the previous sections. After 72 h of
exposure at 37°C and 5% CO2 a subset of wells was
treated with 20 μM FCCP (100 μl/well). The nano-
materials-containing exposure medium was replaced
with medium (100 μl/well). Thereupon, the cells were
incubated for another 10 min at 37°C and then
stained with TMRE prepared in phenol-red MEM +
(final concentration in the well: 0.5 μM). After the
staining period (15 min at 37°C in the dark) the dye
was aspirated and rinsed twice with 0.2% BSA in PBS.
Subsequently the fluorescence intensity was measured
using a Tecan Genios microplate reader equipped
with at 532 and 590 nm excitation and emission
filters, respectively.
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biological samples
Hep G2 cells were seeded onto poly-L-lysine coated
glass coverslips (BD biosciences, Erembodegem, BE) lo-
cated in the wells of a 24-well plate (growth area:
1.9 cm2) (Greiner Bio-One GmbH, DE). The cell number
at time of seeding was 2.0 × 105 cells/well. The medium
volume was 0.5 ml. The plates were incubated overnight
at 37°C and 5% CO2 and thereafter exposed to 16 μg/ml
GO and 32 μg/ml CXYG for 24, 48 or 72 h. Cells ex-
posed to only medium and 10% Milli-Q water were used
as negative and vehicle control, respectively. After the
exposure period, the nanomaterial containing medium
was removed and the cells washed three times with
Millonig buffer (pH 7.3) and then fixed with 4% parafor-
maldehyde and 2.5% glutaraldehyde in Millonig buffer
(pH 7.3). After fixing, the cells were washed twice and
stored in Millonig buffer over night at 4°C. The follow-
ing day, the cells were postfixed in 1% osmium tetroxide
in bidestilled water for 1 h. The cells were rinsed three
times with bidestilled water and subsequently dehy-
drated in an increasing acetone gradient (30, 50, 70, 80,
90, 95 and 100% (2×), sequentially applied in 15 min
steps). For scanning electron microscopy (SEM), follow-
ing dehydration, the samples were critical point-dried,
metalized and analyzed in a JOEL 6400 JSM scanning
electron microscope (JEOL Ltd., Tokyo, JP) operated at
35 kV. For TEM, following dehydration, cells were infil-
trated with Spurr´s resin (Spurr´s resin : acetone (1:3)
for 1 h, Spurr´s resin : acetone (1:1) for 1 h, Spurr´s
resin : acetone (3:1) for 2 h, 100% Spurr´s resin over-
night). The following day, the coverslips with the cell
monolayer were embedded in fresh Spurr´s resin, which
was then left to polymerize at 65°C for 48 h. Afterwards
the coverslip was removed from the cured resin block
by immersing the latter in liquid nitrogen. Subsequently
ultrathin sections were prepared by cutting the resin
block in the plane of the cell monolayer using a Leica
Ultracut E ultramicrotome (Leica Microsystems, Wetzlar,
DE) equipped with a diamante knife. Ultrathin sections
were stained with 1% uranyl acetate in bidestilled water
followed by Reynolds’ lead citrate and then analyzed in a
JOEL 1010 JEM transmission electron microscope (JEOL
Ltd, Tokyo, JP) operated at 100 kV.
Statistical analysis
Results of cytotoxicity, ROS and MMP assays represent
the means and standard errors (SEM) of at least three
independent experiments, in which each treatment was
applied in triplicate. Statistical analysis was performed
using Sigma Plot version 12.0 (Jandel Scientific, San
Rafael, CA, USA). Significant differences among treat-
ments were determined by one-way repeated measures
analysis of variance (rmANOVA, p < 0.05). All data weretested beforehand for normality (Shapiro-Wilk test, p <
0.05) and equal variance (p < 0.05). Significant differ-
ences between treatments and the control were deter-
mined by applying a Dunnett’s Post hoc test. For
comparisons of two groups a Student´s t-test was
performed.Additional files
Additional file 1: Figure S1. Hydrodynamic size distribution of
ultrasonicated GO suspensions in Milli-Q water before and after
centrifugation. DLS measurements performed on the non-centrifuged
dispersions demonstrated low inter-measurement reproducibility (A). DLS
measurements performed on the supernatants of the centrifuged
dispersion demonstrated good inter-measurement reproducibility (B).
Figure S2. Light microscopy images of Hep G2 cells treated with non-
centrifuged and centrifuged GO suspensions. Cells were incubated for 24
h with the suspensions, washed twice with PBS and then analyzed in a
Zeiss Axiovert 25 inverted microscope (100X magnification). Cell cultures
treated with suspensions (100 μg/ml) prepared from the non-centrifuged
stock suspensions were covered with large aggregates/agglomerates
(arrow) (A). In cell cultures treated with suspensions (16 μg/ml) prepared
from the centrifuged stock suspensions no aggregates/agglomerates
were discernible. Figure S3. Estimation of the concentration of GO and
CXYG stock suspensions. A) Standard curves generated from the non-
centrifuged suspensions. B) Absorbance values of the corresponding
supernatants and serial dilutions thereof plotted against the
concentrations estimated using the standard curves shown in A. The
slope of the curve derived from the non-centrifuged suspension was
similar to the slope of the curve derived from the centrifuged suspension
indicating that the agglomeration state of the suspensions had no
influence on their absorptivity. Figure S4. Photograph of GO and CXYG
stock suspensions after eight weeks storage at 4°C. GO and CXYG stock
suspensions demonstrated high colloidal stability. No sedimentation of
GO or GXYG could be observed. Figure S5. Size distribution of platelets
in the GO stock suspension established on the basis of surface area
measurements in AFM topographical images. Figure S6. AFM
topographical image of the GO stock solution. In addition to GO
nanoplatelets with lateral dimensions in the lower nanometer range (cp.
Results, Figure 2A), few platelets with sizes from several hundred
nanometers to a few micrometers were identified.
Additional file 2: Figure S1. Influence of culture medium composition
on colloidal stability of GO and CXYG nanoplatelets. GO and CXYG stock
suspensions were diluted 1:10 in three different complex cell culture
media (A and B, respectively): MEM, MEM supplemented with 1% L-Gln
and 1% P/S, and MEM supplemented with 1% L-Gln, 1% P/S and 10%
FBS. The photographs were taken 10 minutes after preparation of the
samples. Medium supplementation with FBS was essential to obtain
dispersion with high colloidal stability. The presence of L-Gln and P/S did
accelerate GO and CXYG nanoplatelet flocculation and sedimentation.
Figure S2. Hydrodynamic size distribution in GO suspensions as function
of concentration and incubation time. DLS analysis was performed on
serial dilutions of a GO suspensions prepared in serum-supplemented
culture medium (16 μg/ml). The samples were analyzed directly after
preparation and after incubation at 37°C for 48 and 120 h, respectively.
No significant change in the size distribution profile was observed as
function of sample concentration or incubation time. Figure S3. Hydrodynamic
size distribution in CXYG suspensions as function of concentration and
incubation time. DLS analysis was performed on serial dilutions of a CXYG
dispersion prepared in serum-supplemented culture medium (32 μg/ml).
The samples were analyzed directly after preparation and after incubation at
37°C for 48 and 120 h, respectively. No significant change in the size
distribution profile was observed as function of sample concentration or
incubation time. Figure S4. Hydrodynamic size distribution profile of serum-
supplemented MEM.
Additional file 3: Figure S1. Three-dimensional (3D) fluorescence
spectra of GO and CXYG stock suspensions. A) 3D fluorescence spectrum
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of a 10 μg/ml CXYG/Milli-Q water dispersions. C) 3D fluorescence
spectrum of Milli-Q water (blank). Figure S2. Redox-reaction of
alamarBlue with GO and CXYG in absence of cells. AlamarBlue dissolved
in phenol red-free medium without FBS was incubated with inreasing
concentrations of GO and CXYG (0.2 – 100 μg/ml) at 37°C for 30 min. No
reduction of alamarBlue was observed.
Additional file 4: Figure S1. SEM micrographs of Hep G2 cells
exposed to 16 and 32 μg/ml GO and CXYG for 72. Image A shows a SEM
micrograph of untreated cells. Image B shows cells treated with 32 μg/ml
CXYG. Image C shows cells treated with 16 μg/ml GO. The boxed-in area
is shown at higher magnification in image D. Scale bares are 30 μm in A
and B, 50 μm in C and 4 μm in D. White arrows exemplarily indicate
apoptotic cells (communication with Dr. Covadonga Alonso,
Departamento de Biotecnología, Instituto Nacional de Investigación y
Tecnología Agraria y Alimentaria, INIA) being detached from the
substrate and neighboring cells, and characterized by a round cell shape
and plasma membrane blebbing. Figure S2. Differential cytotoxicity of
GO and CXYG.
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